About ViaCyte
ViaCyte is a company based in San Diego (United States) founded in 1999 was acquired by Vertex Pharmaceuticals in July 2022.. ViaCyte has raised $389.03 million across 18 funding rounds from investors including CRISPR Therapeutics, Johnson & Johnson and Vertex Pharmaceuticals. The company has 126 employees as of December 31, 2022. ViaCyte operates in a competitive market with competitors including Rhythm Pharmaceuticals, MannKind Corp, NGM Biopharmaceuticals, Sana Biotechnology and Semma Therapeutics, among others.
- Headquarter San Diego, United States
- Employees 126 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Viacyte, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$389.03 M (USD)
in 18 rounds
-
Latest Funding Round
$115 M (USD), Series D
Jun 09, 2021
-
Investors
CRISPR Therapeutics
& 21 more
-
Employee Count
126
as on Dec 31, 2022
-
Acquired by
Vertex Pharmaceuticals
(Jul 11, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Leadership Team
249 people
Software Development Team
218 people
Senior Team
136 people
Principal Team
61 people
Finance and Accounting
53 people
Operations Team
35 people
Legal and Compliance
34 people
Sales and Marketing
30 people
Unlock access to complete
Funding Insights of ViaCyte
ViaCyte has successfully raised a total of $389.03M across 18 strategic funding rounds. The most recent funding activity was a Series D round of $115 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 18
- Last Round Series D — $115.0M
-
First Round
First Round
(16 Jul 2007)
- Investors Count 21
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2021 | Amount | Series D - ViaCyte | Valuation | TPG , Sanderling Ventures | |
| Apr, 2021 | Amount | Series D - ViaCyte | Valuation | RA Capital Management , Sanderling Ventures |
|
| Apr, 2020 | Amount | Series D - ViaCyte | Valuation | Sanderling Ventures , RA Capital Management |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ViaCyte
ViaCyte has secured backing from 22 investors, including venture fund and institutional investors. Prominent investors backing the company include CRISPR Therapeutics, Johnson & Johnson and Vertex Pharmaceuticals. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Fund of funds focused on pre-seed and seed-stage companies
|
Founded Year | Domain | Location | |
|
Biomedical investment financing and active management services.
|
Founded Year | Domain | Location | |
|
Long-term private equity investments in transformational opportunities are pursued.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ViaCyte
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - ViaCyte
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Viacyte Comparisons
Competitors of ViaCyte
ViaCyte operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Rhythm Pharmaceuticals, MannKind Corp, NGM Biopharmaceuticals, Sana Biotechnology and Semma Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| domain | founded_year | HQ Location |
Developer of small-molecule drugs
|
|
| domain | founded_year | HQ Location |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| domain | founded_year | HQ Location |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment
|
|
| domain | founded_year | HQ Location |
Therapeutics for diabetes and obesity treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Viacyte
Frequently Asked Questions about ViaCyte
When was ViaCyte founded?
ViaCyte was founded in 1999 and raised its 1st funding round 8 years after it was founded.
Where is ViaCyte located?
ViaCyte is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Is ViaCyte a funded company?
ViaCyte is a funded company, having raised a total of $389.03M across 18 funding rounds to date. The company's 1st funding round was a Series D of $32.65M, raised on Jul 16, 2007.
How many employees does ViaCyte have?
As of Dec 31, 2022, the latest employee count at ViaCyte is 126.
What does ViaCyte do?
ViaCyte was founded in 1999 in San Diego, United States, within the biotechnology sector. Operations center on advancing cell-based treatments for diabetes. The primary candidate, VC-01, involves pancreatic progenitor cells sourced from human pluripotent stem cells, which are placed in an implantable encapsulation device. Upon maturation post-implantation, insulin and regulatory factors are secreted by these cells in response to glucose levels, targeting sustained management without immunosuppression or related risks.
Who are the top competitors of ViaCyte?
ViaCyte's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Corcept.
Who are ViaCyte's investors?
ViaCyte has 22 investors. Key investors include CRISPR Therapeutics, Johnson & Johnson, Vertex Pharmaceuticals, W. L. Gore & Associates, and TPG.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.